Lantern Pharma Uses AI to Transform Cancer Drug Development With Promising Trial Results

Lantern Pharma is leveraging artificial intelligence and big data to revolutionize cancer drug development, significantly reducing costs and timelines while improving success rates. CEO Panna Sharma highlights how the company has cut early-stage development time by up to 80% and is advancing multiple clinical trials, including its lead candidate LP-184, which has shown strong disease control rates in hard-to-treat cancers.

The company is also expanding its AI platform capabilities, launching tools like Zeta to accelerate rare cancer research and enable faster discovery. With multiple FDA designations, ongoing trials, and global expansion, Lantern Pharma aims to redefine precision oncology and partner with larger pharmaceutical companies for commercialization.

#LanternPharma
#Biotech
#ArtificialIntelligence
#CancerResearch
#DrugDevelopment
#ClinicalTrials
#PrecisionMedicine
#Oncology
#HealthcareInnovation
#AIinHealthcare
#BiotechInvesting
#MedicalBreakthrough
#FDA
#Pharmaceuticals
#NewsOut